3681 — Sinomab Bioscience Income Statement
0.000.00%
Last trade - 00:00- HK$2.46bn
- HK$2.87bn
- CNY2.03m
Annual income statement for Sinomab Bioscience, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 25.9 | 0 | 1.36 | 2.03 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 0.422 | 0.543 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 119 | 304 | 274 | 238 | 179 |
| Operating Profit | -119 | -278 | -274 | -237 | -176 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -123 | -288 | -284 | -243 | -185 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -123 | -288 | -284 | -243 | -185 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -123 | -288 | -284 | -243 | -185 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -123 | -288 | -284 | -243 | -185 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.122 | -0.29 | -0.304 | -0.238 | -0.161 |